YOLFTbeta
bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc.

BIAF · NASDAQ · Healthcare / Diagnostics & Research

2.20USD-0.14 (-5.98%)

Price History

Full chart

Market Stats

Previous Close2.34
Open2.34
Day Range2.17 – 2.35
52-Week Range4.56 – 80.70
Volume51.06K
Market Cap4.70M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.35
Dividend Yield0.00%
Beta-1.11
50-Day Avg8.15
200-Day Avg21.25

About

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMs. Maria Zannes J.D.
  • Employees57
  • Headquarters3300 Nacogdoches Road, San Antonio, TX, United States, 78217, USA
  • Websitehttps://bioaffinitytech.com

Leadership

  • Mr. Steven GirgentiFounder & Executive Chairman of the Board · b. 1946
  • Ms. Maria Zannes J.D.Founder, President, CEO & Director · b. 1956
  • Mr. James Michael Edwards CPA, M.B.A.Chief Financial Officer · b. 1967
  • Mr. Xavier T. Reveles M.S.Chief Operating Officer · b. 1969
  • Dr. William Bauta Ph.D.Chief Science Officer
  • Mr. Timothy P. Zannes J.D.Executive VP, Secretary & General Counsel · b. 1953
  • Ms. Julie Anne OvertonDirector of Communications
  • Mr. Dallas J. ColemanVice President of sales
  • Dr. Gordon Downie M.D., Ph.D.Chief Medical Officer

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-01.31K4.80K2.53M9.36M6.16M
Growth (%)---+267.76%+52617.05%+269.75%-34.18%
Cost of Revenue40.28K22.24K4.82K4671.74M5.98M4.73M
Gross Profit-40.28K-22.24K-4.82K4.34K791.62K3.38M1.43M
Gross Margin---368.84%90.28%31.26%36.09%23.21%
Operating Expense3.05M2.58M2.20M4.02M8.76M12.33M12.00M
Operating Income-3.09M-2.60M-2.21M-4.01M-7.97M-8.95M-10.57M
Operating Margin---168975.65%-83511.51%-314.89%-95.63%-171.58%
EBITDA-3.05M-6.86M-5.32M-5.61M-7.63M-8.33M-14.32M
EBITDA Margin---407181.62%-116777.68%-301.30%-88.98%-232.34%
Net Income-3.31M-7.27M-6.33M-8.15M-7.94M-9.04M-14.91M
Net Income Margin---484411.41%-169771.25%-313.47%-96.56%-241.96%
R&D1.85M1.61M1.14M1.52M1.73M1.78M2.09M
R&D as % of Total Revenue--87132.54%31733.71%68.13%19.05%33.90%
Interest Expense214.83K382.17K1.00M2.53M37.13K92.47K44.37K
Interest Expense % of Total Revenue--76722.82%52737.87%1.47%0.99%0.72%

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets658.81K145.60K1.45M12.18M8.22M6.51M10.96M
Total Liabilities4.69M15.22M17.24M1.14M3.37M3.91M3.68M
Total Equity-4.04M-15.07M-15.79M11.04M4.86M2.60M7.28M
Cash578.48K83.11K1.36M11.41M2.82M1.11M6.45M
Total Debt4.01M10.01M11.36M251.75K1.58M1.50M1.16M
Net Debt3.43M9.92M10.00M-11.16M-1.24M395.90K-5.29M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.49M-2.21M-2.05M-4.07M-6.04M-7.26M-9.33M
Investing Cash Flow-11.40K-2.89K--219.99K-2.21M-79.08K-60.57K
Financing Cash Flow2.33M1.72M3.33M14.34M-344.98K5.63M14.73M
Capital Expenditure11.40K2.89K2219.99K22.90K79.08K60.57K
Free Cash Flow-2.50M-2.21M-2.05M-4.29M-6.06M-7.34M-9.39M
Dividends Paid---185---
FCF to OCF100.46%100.13%100.00%105.40%100.38%101.09%100.65%
Dividend Paid to FCF----0.00%---

Earnings

Report DateJun 16, 2022Sep 2, 2022Nov 30, 2022Mar 31, 2023May 15, 2023Aug 14, 2023Nov 14, 2023Mar 5, 2024May 15, 2024Aug 14, 2024Nov 14, 2024Mar 31, 2025May 15, 2025Aug 14, 2025Nov 14, 2025Mar 13, 2026May 8, 2026Aug 7, 2026Nov 13, 2026
EPS Estimate---1.17-0.19-0.18-0.20-0.15-0.20-0.20-0.17-0.15-0.14-0.17-0.10-2.70----
EPS Actual-0.48-0.03-1.17-0.19-0.18-0.20-0.260.00-0.26-0.19-0.16-0.19-0.16-0.17-4.74-10.46-0.81-0.64-
Surprise--0.00%0.00%0.00%0.00%-73.33%100.00%-28.35%-11.76%-6.67%-35.71%5.88%-70.00%-75.56%----
Timing------After-hoursPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market----

Key Statistics & Ratios

Market Cap4.70M
Enterprise Value3.72M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.80
Price / Book1.25
EPS-1.35
Book Value8.34
Revenue (TTM)5.90M
Gross Profit (TTM)2.04M
EBITDA-11.97M
Profit Margin-257.33%
Operating Margin-220.77%
Return on Equity-1860.15%
Return on Assets-125.11%
Shares Outstanding600.74K
Shares Float532.26K
Beta-1.11
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 1 analystsTarget 6.00
  • Hold
    1

Ownership Breakdown

Institutions
5.62%
Insiders
0.82%
Retail / Other
93.56%

Top Institutional Holders

  • Vanguard Capital Management, LLC
    55.54K1.23%
  • Geode Capital Management, LLC
    48.29K1.07%
  • J. Safra Sarasin Holding AG
    42.60K0.95%
  • Vanguard Fiduciary Trust Co
    31.07K0.69%
  • Schonfeld Strategic Advisors LLC
    24.41K0.54%
  • State Street Corp
    14.39K0.32%
  • Northern Trust Corp
    12.72K0.28%
  • UBS Group AG
    9.21K0.20%
  • Tower Research Capital LLC
    2.06K0.05%
  • EMC Capital Management(TX)
    2.00K0.04%
  • Ameritas Advisory Services, LLC
    1.00K0.02%
  • IFP Advisors, LLC
    8330.02%
  • Citigroup Inc
    570.00%
  • Morgan Stanley - Brokerage Accounts
    30.00%
  • Caitong International Asset Management Co., Limited.
    10.00%
  • Citadel Advisors Llc
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    24.89K0.55%
  • Fidelity Total Market Index
    7.64K0.17%
  • Fidelity Series Total Market Index
    6.52K0.14%
  • Fidelity Nasdaq Composite Index
    2.50K0.06%

Stock Splits

  • Aug 24, 20261:15
  • Sep 19, 20251:30